Drugs / MK-6204
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06726369 | Dec 2024 → Dec 2029 expected | cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-6204 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06726369 ↗ |
| Known as | SKB535 | “Several dose levels of MK-6204 (SKB535) for Injection are planned and administered every 3 weeks.” NCT06726369 ↗ |